



ASX ANNOUNCEMENT

Actinogen receives additional \$0.5 million¹ binding commitment for any rights issue offer shortfall

Sydney, 30 August 2023. Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that it has received an additional \$0.5 million in binding shortfall commitments for its \$10 million non-renounceable rights offer (also known as an entitlement offer) to existing shareholders,² which is open until **7pm Monday 4 September 2023**.

The new underwriting commitment from **Forrest Capital Pty Ltd** brings the total underwriting commitment for any shortfall that arises from the rights issue offer to \$5.06 million.

To recap, the rights issue offer allows shareholders to:

- Acquire 1 new share for every 4.54 Shares held at an issue price of 2.5 cents per new share
- Receive for no additional payment 1 new unlisted option (with an exercise price of 3.75 cents and an expiry date 36 months from the date of issue) for every 2 new shares issued
- Apply for any number of additional shares (and corresponding new options) if shareholders subscribe for their full pro rata entitlement initially (known as a top up offer)

Please note that new share subscriptions from existing shareholders, including the top up offer amounts, will be allocated prior to any remaining allocation to shortfall investors.

If shareholders have not yet received a letter via email or mail about the offer with its unique payment identifier number for each holding, please contact the Company’s share registrar, Automic, to register your email address for urgent delivery of your personalized offer document (including instructions on how to participate in the offer). Alternatively, speak with a Vested Equities advisor.

Contact Automic	Contact Vested Equities
If you have any questions in relation to the current rights issue or your shareholding in Actinogen, please contact Automic at: hello@automicgroup.com.au or 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia)	To receive a strategic update on Actinogen’s activities and more information on the entitlement offer please contact: Harley McKinnirey Head of Investor Relations at Vested Equities 07 55 555 015.

¹ Unless stated otherwise, all financial data is quoted in Australian dollars

² For shares held as at the Record Date of 14 August 2023

<p>Visit the Automic website https://investor.automic.com.au/#/home to register as an ACW shareholder or log in to your existing account.</p>	
---	--

An alternative point of contact, particularly for those shareholders who have not received their entitlement letter via email or mail with details on how to access their unique offer payment identifier number, is the Actinogen Company Secretary, Mr Peter Webse: pwebse@governancecorp.com.au

ENDS

Investors

Dr. Steven Gourlay
 CEO & Managing Director
 P: +61 2 8964 7401

E. steven.gourlay@actinogen.com.au

Michael Roberts
 Investor Relations
 M: +61 423 866 231

E. michael.roberts@actinogen.com.au

Announcement authorised by the Board of Directors of Actinogen Medical

About Vested Equities

Vested Equities acts as a consultant to inform shareholders about the rights issue offer and measure the overall sentiment of a company's shareholders to assist the company to understand how investor relations, communications, and distribution strategies can be optimized.

About Actinogen Medical

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.

Cognitive function means how a person understands, remembers and thinks clearly. Cognitive functions include memory, attention, reasoning, awareness and decision-making.

Actinogen is currently developing its lead compound, Xanamem,[®] as a promising new therapy for Alzheimer's Disease and Depression and hopes to study Fragile X Syndrome and other neurological and psychiatric diseases in the future. Reducing cortisol inside brain cells could have a positive impact in these and many other diseases. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

Current and Upcoming Clinical Trials

The **XanaCIDD Phase 2a depression trial** is a double-blind, six-week proof-of-concept, placebo-controlled, parallel group design trial in 160 patients. Patients are evenly randomized to receive Xanamem 10 mg once daily or placebo, in some cases in addition to their existing antidepressant therapy, and effects on cognition and depression are assessed.

The **XanaMIA Phase 2b Alzheimer's disease trial** is a double-blind, 36-week treatment, placebo-controlled, parallel group design trial in 330 patients with mild to moderate AD and progressive disease, determined by clinical criteria and

[®] Xanamem is a registered trademark of Actinogen Medical Limited

confirmed by an elevated level of pTau181 protein in blood. Patients receive Xanamem 5 mg or 10 mg, or placebo, once daily, and effects on cognition, function and progression of Alzheimer's disease are assessed. Thus, Xanamem is being assessed in this trial for its potential effects as both a cognitive enhancer and a disease course modifier.

About Xanamem

Xanamem's novel mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11 β -HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing.

Chronically elevated cortisol is associated with cognitive decline in Alzheimer's Disease and excess cortisol is known to be toxic to brain cells. Cognitive impairment is also a feature in Depression and many other diseases. Cortisol itself is also associated with depressive symptoms and when targeted via other mechanisms has shown some promise in prior clinical trials.

The Company has studied 11 β -HSD1 inhibition by Xanamem in more than 300 volunteers and patients, so far finding a statistically significant improvement in working memory and attention, compared with placebo, in healthy, older volunteers in two consecutive trials and clinically significant improvements in functional and cognitive ability in patients with biomarker-positive mild AD. Previously, high levels of target engagement in the brain with doses as low as 5 mg daily have been demonstrated in a human PET imaging study. A series of Phase 2 studies in multiple diseases is being conducted to further confirm and characterize Xanamem's therapeutic potential.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical.

Disclaimer

This announcement and attachments may contain certain "forward-looking statements" that are not historical facts; are based on subjective estimates, assumptions and qualifications; and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements should be considered "at-risk statements" - not to be relied upon as they are subject to known and unknown risks, uncertainties and other factors (such as significant business, economic and competitive uncertainties / contingencies and regulatory and clinical development risks, future outcomes and uncertainties) that may lead to actual results being materially different from any forward looking statement or the performance expressed or implied by such forward looking statements. You are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Actinogen Medical does not undertake any obligation to revise such statements to reflect events or any change in circumstances arising after the date hereof, or to reflect the occurrence of or non-occurrence of any future events. Past performance is not a reliable indicator of future performance. Actinogen Medical does not make any guarantee, representation or warranty as to the likelihood of achievement or reasonableness of any forward-looking statements and there can be no assurance or guarantee that any forward-looking statements will be realised.

ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP.